Table 1.
Patient characteristics categorized by preoperative and postoperative NLR
| Characteristics | Total | Group I Preoperative NLR ≤ 2.5 Postoperative NLR ≤ 1.5 |
Group II Preoperative NLR ≤ 2.5 Postoperative NLR > 1.5 |
Group III Preoperative NLR > 2.5 Postoperative NLR ≤ 1.5 |
Group IV Preoperative NLR > 2.5 Postoperative NLR > 1.5 |
p-value |
|---|---|---|---|---|---|---|
| (N = 2742) | (n = 858) | (n = 478) | (n = 511) | (n = 895) | ||
| Age, years | 62.0 (53.0–70.0) | 60.0 (53.0–67.0) | 63.0 (54.0–71.0) | 61.0 (50.0–68.0) | 63.0 (53.0–72.0) | < 0.001 |
| 18–64 | 1646 (60.0) | 566 (66.0) | 266 (55.6) | 320 (62.6) | 494 (55.2) | < 0.001 |
| ≥ 65 | 1096 (40.0) | 292 (34.0) | 212 (44.4) | 191 (37.4) | 401 (44.8) | |
| Sex | 0.319 | |||||
| Male | 1474 (53.8) | 454 (52.9) | 246 (51.5) | 271 (53.0) | 503 (56.2) | |
| Female | 1268 (46.2) | 404 (47.1) | 232 (48.5) | 240 (47.0) | 392 (43.8) | |
| Chemotherapy | < 0.001 | |||||
| IRI, OXA | 1790 (65.3) | 602 (70.2) | 299 (62.6) | 373 (73.0) | 516 (57.7) | |
| 5FU, others | 580 (21.2) | 173 (20.2) | 111 (23.2) | 95 (18.6) | 201 (22.5) | |
|
Chemotherapy < 4 times/ duration < 3 months/ no chemotherapy |
372 (13.6) | 83 (9.7) | 68 (14.2) | 43 (8.4) | 178 (19.9) | |
| Comorbidity | ||||||
| DM | 607 (22.1) | 156 (18.2) | 122 (25.5) | 93 (18.2) | 236 (26.4) | < 0.001 |
| HTN | 1094 (39.9) | 291 (33.9) | 217 (45.4) | 172 (33.7) | 414 (46.3) | < 0.001 |
| CAD | 144 (5.3) | 35 (4.1) | 28 (5.9) | 23 (4.5) | 58 (6.5) | 0.111 |
| CVA | 117 (4.3) | 22 (2.6) | 23 (4.8) | 11 (2.2) | 61 (6.8) | < 0.001 |
| CKD | 102 (3.7) | 9 (1.0) | 18 (3.8) | 13 (2.5) | 62 (6.9) | < 0.001 |
| COPD/Asthma | 128 (4.7) | 22 (2.6) | 19 (4.0) | 25 (4.9) | 62 (6.9) | < 0.001 |
| Tumor location | < 0.001 | |||||
| Right | 1182 (43.1) | 327 (38.1) | 180 (37.7) | 254 (49.7) | 421 (47.0) | |
| Left | 1560 (56.9) | 531 (61.9) | 298 (62.3) | 257 (50.3) | 474 (53.0) | |
| T stage | < 0.001 | |||||
| 1, 2 | 233 (8.5) | 101 (11.8) | 63 (13.2) | 16 (3.1) | 53 (5.9) | |
| 3 | 1585 (57.8) | 534 (62.2) | 281 (58.8) | 263 (51.5) | 507 (56.6) | |
| 4 | 924 (33.7) | 223 (26.0) | 134 (28.0) | 232 (45.4) | 335 (37.4) | |
| N stage | 0.955 | |||||
| 1 | 1705 (62.2) | 527 (61.4) | 298 (62.3) | 319 (62.4) | 561 (62.7) | |
| 2 | 1037 (37.8) | 331 (38.6) | 180 (37.7) | 192 (37.6) | 334 (37.3) | |
| Histologic Grade | < 0.001 | |||||
| Well, moderately differentiated | 1750 (63.8) | 595 (69.3) | 320 (66.9) | 301 (58.9) | 534 (59.7) | |
| Poorly differentiated, Undifferentiated | 301 (11.0) | 67 (7.8) | 43 (9.0) | 75 (14.7) | 116 (13.0) | |
| Unknown | 691 (25.2) | 196 (22.8) | 115 (24.1) | 135 (26.4) | 245 (27.4) | |
| CEA, ng/mL | < 0.001 | |||||
| Normal (< 5) | 1381 (50.4) | 454 (52.9) | 281 (58.8) | 243 (47.6) | 403 (45.0) | |
| Elevated (≥ 5) | 862 (31.4) | 230 (26.8) | 101 (21.1) | 197 (38.6) | 334 (37.3) | |
| Unknown | 499 (18.2) | 174 (20.3) | 96 (20.1) | 71 (13.9) | 158 (17.7) | |
| WBC, 103/µL | 7 (5.8–8.6) | 6.3 (5.3–7.4) | 6.2 (5.3–7.4) | 8.2 (6.6–10.3) | 7.8 (6.3–9.8) | < 0.001 |
| RBC, 106/µL | 4.41 (4.0–4.8) | 4.5 (4.1–4.8) | 4.39 (4.0–4.8) | 4.41 (4.0–4.8) | 4.33 (3.9–4.8) | < 0.001 |
| Platelet, 103/µL | 272.0 (220.0–341.0) | 256.5 (211.0–319.0) | 251.5 (209.0–312.0) | 303 (241.0–387.0) | 284 (225.0–354.0) | < 0.001 |
| RDW, % | 13.8 (13.0–16.1) | 13.5 (12.9–14.9) | 13.5 (12.8–15.0) | 14.5 (13.2–17.3) | 14.4 (13.1–17.0) | < 0.001 |
| Hemoglobin, g/dL | 12.1 (10.0–13.7) | 12.7 (11.0–14.0) | 12.4 (10.6–13.7) | 11.6 (9.6–13.3) | 11.5 (9.5–13.4) | < 0.001 |
| MCV, fL | 85.9 (77.2–90.2) | 87.5 (80–91.1) | 87.0 (79.5–90.4) | 83.9 (74.8–89.4) | 84.8 (76.1–89.5) | < 0.001 |
| Segment, % | 65.4 (58.7–72.3) | 57.5 (52.5–61.7) | 60.0 (56.0–63.0) | 71.9 (67.9–77.0) | 72.2 (68.4–77.7) | < 0.001 |
| Lymphocyte, % | 25.8 (18.9–31.8) | 32.9 (29.6–37.8) | 30.4 (28.0–34.0) | 19.7 (14.9–23.6) | 18.8 (14.0–22.5) | < 0.001 |
| Albumin, g/dL | 4.2 (3.8–4.4) (n = 2587) | 4.3 (4.0–4.5) (n = 834) | 4.3 (4.0–4.5) (n = 460) | 4.0 (3.5–4.3) (n = 467) | 4.0 (3.6–4.4) (n = 826) | < 0.001 |
| CEA, ng/mL | 3.4 (1.7–9.0) (n = 2243) | 3.0 (1.5–6.9) (n = 684) | 2.6 (1.4–5.3) (n = 382) | 4.1 (1.8–11.3) (n = 440) | 4.2 (2.1–13.2) (n = 737) | < 0.001 |
| NLR | 2.5 (1.9–3.8) | 1.8 (1.4–2.1) | 2.0 (1.7–2.3) | 3.65 (2.9–5.1) | 3.9 (3.0–5.5) | < 0.001 |
| PLR | 1.6 (1.2–2.3) | 1.2 (0.9–1.6) | 1.3 (1.0–1.7) | 2.1 (1.6–2.8) | 2.1 (1.5–2.9) | < 0.001 |
| Hemoglobin, g/dL a | < 0.001 | |||||
| Low | 1643 (59.9) | 429 (50.0) | 266 (55.6) | 341 (66.7) | 607 (67.8) | |
| Normal | 1099 (40.1) | 429 (50.0) | 212 (44.4) | 170 (33.3) | 288 (32.2) | |
| Albumin, g/dL | < 0.001 | |||||
| > 3.5 | 2194 (80.0) | 788 (91.8) | 426 (89.1) | 353 (69.1) | 627 (70.1) | |
| ≤ 3.5 | 393 (14.3) | 46 (5.4) | 34 (7.1) | 114 (22.3) | 199 (22.2) | |
| Unknown | 155 (5.7) | 24 (2.8) | 18 (3.8) | 44 (8.6) | 69 (7.7) |
Continuous variables are presented as median (IQR); categorical variables are presented as count (percentage)
p-values < 0.05 are shown in bold
DM diabetes mellitus, HTN hypertension, CAD coronary artery disease, CVA cardiovascular accident, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CEA carcinoembryonic antigen, IRI irinotecan, OXA oxaliplatin, HR hazard ratio, aHR adjusted hazard ratio, CI confidence interval, RDW red cell distribution width, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, WBC white blood cell, RBC red blood cell, MCV mean corpuscular volume
aMale ≤ 13.5 g/dL, female ≤ 12 g/Dl